These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 16413390)

  • 1. MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes.
    Mayr C; Bund D; Schlee M; Bamberger M; Kofler DM; Hallek M; Wendtner CM
    Exp Hematol; 2006 Jan; 34(1):44-53. PubMed ID: 16413390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes.
    Mayr C; Bund D; Schlee M; Moosmann A; Kofler DM; Hallek M; Wendtner CM
    Blood; 2005 Feb; 105(4):1566-73. PubMed ID: 15471955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes.
    Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
    Exp Hematol; 2007 Jun; 35(6):920-30. PubMed ID: 17533046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human Ly9 (CD229) as novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (B-CLL) recognized by autologous CD8+ T cells.
    Bund D; Mayr C; Kofler DM; Hallek M; Wendtner CM
    Exp Hematol; 2006 Jul; 34(7):860-9. PubMed ID: 16797413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins.
    Asai T; Storkus WJ; Mueller-Berghaus J; Knapp W; DeLeo AB; Chikamatsu K; Whiteside TL
    Cancer Immun; 2002 Apr; 2():3. PubMed ID: 12747748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
    Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
    Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancement of the antigen-specific cytotoxic T lymphocyte-inducing ability in the PMDC11 leukemic plasmacytoid dendritic cell line via lentiviral vector-mediated transduction of the caTLR4 gene.
    Iwabuchi M; Narita M; Uchiyama T; Iwaya S; Oiwa E; Nishizawa Y; Hashimoto S; Bonehill A; Kasahara N; Takizawa J; Takahashi M
    Mol Med Rep; 2015 Aug; 12(2):2443-50. PubMed ID: 25936433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells.
    Buhmann R; Nolte A; Westhaus D; Emmerich B; Hallek M
    Blood; 1999 Mar; 93(6):1992-2002. PubMed ID: 10068672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia.
    Giannopoulos K; Dmoszynska A; Kowal M; Rolinski J; Gostick E; Price DA; Greiner J; Rojewski M; Stilgenbauer S; Döhner H; Schmitt M
    Leukemia; 2010 Apr; 24(4):798-805. PubMed ID: 20220777
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD8 T-cell recognition of human 5T4 oncofetal antigen.
    Smyth LJ; Elkord E; Taher TE; Jiang HR; Burt DJ; Clayton A; van Veelen PA; de Ru A; Ossendorp F; Melief CJ; Drijfhout JW; Dermime S; Hawkins RE; Stern PL
    Int J Cancer; 2006 Oct; 119(7):1638-47. PubMed ID: 16646078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoreactive, cytotoxic T lymphocytes specific for peptides derived from normal B-cell differentiation antigens in healthy individuals and patients with B-cell malignancies.
    Grube M; Rezvani K; Wiestner A; Fujiwara H; Sconocchia G; Melenhorst JJ; Hensel N; Marti GE; Kwak LW; Wilson W; Barrett JA
    Clin Cancer Res; 2004 Feb; 10(3):1047-56. PubMed ID: 14871984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays.
    Britten CM; Meyer RG; Kreer T; Drexler I; Wölfel T; Herr W
    J Immunol Methods; 2002 Jan; 259(1-2):95-110. PubMed ID: 11730845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells.
    Mayr C; Kofler DM; Büning H; Bund D; Hallek M; Wendtner CM
    Blood; 2005 Nov; 106(9):3223-6. PubMed ID: 16014560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic lymphocytic leukemia-reactive T cells during disease progression and after autologous tumor cell vaccines.
    Gitelson E; Hammond C; Mena J; Lorenzo M; Buckstein R; Berinstein NL; Imrie K; Spaner DE
    Clin Cancer Res; 2003 May; 9(5):1656-65. PubMed ID: 12738718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.
    Kronenberger K; Nössner E; Frankenberger B; Wahl U; Dreyling M; Hallek M; Mocikat R
    J Immunother; 2008 Oct; 31(8):723-30. PubMed ID: 18779747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.
    Weng J; Rawal S; Chu F; Park HJ; Sharma R; Delgado DA; Fayad L; Fanale M; Romaguera J; Luong A; Kwak LW; Neelapu SS
    Blood; 2012 Aug; 120(8):1613-23. PubMed ID: 22645177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate.
    Goddard RV; Prentice AG; Copplestone JA; Kaminski ER
    Clin Exp Immunol; 2001 Oct; 126(1):16-28. PubMed ID: 11678895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
    Vikman S; Giandomenico V; Sommaggio R; Oberg K; Essand M; Tötterman TH
    Cancer Immunol Immunother; 2008 Mar; 57(3):399-409. PubMed ID: 17717663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of HLA-A*0201-presented T cell epitopes derived from the oncofetal antigen-immature laminin receptor protein in patients with hematological malignancies.
    Siegel S; Wagner A; Friedrichs B; Wendeler A; Wendel L; Kabelitz D; Steinmann J; Barsoum A; Coggin J; Rohrer J; Dreger P; Schmitz N; Zeis M
    J Immunol; 2006 Jun; 176(11):6935-44. PubMed ID: 16709854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The shared tumor associated antigen cyclin-A2 is recognized by high-avidity T-cells.
    Kondo E; Maecker B; Draube A; Klein-Gonzalez N; Shimabukuro-Vornhagen A; Schultze JL; von Bergwelt-Baildon MS
    Int J Cancer; 2009 Nov; 125(10):2474-8. PubMed ID: 19681121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.